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PET/CT and β3-adrenergic receptor activation
M Reza Mirbolooki, Cristian C Constantinescu, Min-Liang Pan and Jogeshwar Mukherjee*
Abstract
Background: Brown adipose tissue [BAT] metabolism in vivo is vital for the development of novel strategies in
combating obesity and diabetes. Currently, BAT is activated at low temperatures and measured using 2-deoxy-2-
18F-fluoro-D-glucose [18F-FDG] positron-emission tomography [PET]. We report the use of b3-adrenergic receptor-
mediated activation of BAT at ambient temperatures using (R, R)-5-[2-[2,3-(3-chlorphenyl)-2-hydroxyethyl-amino]
propyl]-1,3-benzodioxole-2,2-dicarboxylate, disodium salt [CL316,243] (a selective b3-adrenoceptor agonist) and
measured by 18F-FDG PET/computed tomography [CT].
Methods: Control and CL316,243-treated (2 mg/kg) male Sprague-Dawley rats were administered with 18F-FDG for
PET/CT studies and were compared to animals at cold temperatures. Receptor-blocking experiments were carried
out using propranolol (5 mg/kg). Dose effects of CL316,243 were studied by injecting 0.1 to 1 mg/kg 30 min prior
to 18F-FDG administration. Imaging results were confirmed by autoradiography, and histology was done to confirm
BAT activation.
Results: CL316,243-activated interscapular BAT [IBAT], cervical, periaortic, and intercostal BATs were clearly
visualized by PET. 18F-FDG uptake of IBAT was increased 12-fold by CL316,243 vs. 1.1-fold by cold exposure when
compared to controls. 18F-FDG uptake of the CL-activated IBAT was reduced by 96.0% using intraperitoneal
administration of propranolol. Average 18F-FDG uptake of IBAT increased 3.6-, 3.5-, and 7.6-fold by doses of 0.1, 0.5,
and 1 mg/kg CL, respectively. Ex vivo 18F-FDG autoradiography and histology of transverse sections of IBAT
confirmed intense uptake in the CL-activated group and activated IBAT visualized by PET.
Conclusion: Our study indicated that BAT metabolic activity could be evaluated by 18F-FDG PET using CL316,243
at ambient temperature in the rodent model. This provides a feasible and reliable method to study BAT
metabolism.
Keywords: BAT, CL316,243, β3-adrenoceptor, 18F-FDG, obesity
Introduction
The brown adipose tissue [BAT] plays a critical role in
regulating body fat stores and may hold promise in
combating obesity and diabetes given its extraordinary
metabolic capacity [1,2]. Brown adipocytes are rich in
mitochondria with densely packed cristae expressing
uncoupling protein-1 [UCP-1]. They use lipids and car-
bohydrates to generate heat by uncoupling electron
transport from oxidative phosphorylation [3]. The
physiologic consequence of this function is an unrest-
rained oxidation by drawing lipids and carbohydrates
from outside the cell [4]. BAT has also been found to
be important in understanding the mechanism of insulin
resistance [5], reducing adiposity, and improving type 2
diabetes [6] which make it a valuable target to study the
pathogenicity of obesity and diabetes.
Measuring the metabolic activity of BAT and assessing
the factors that influence BAT activity are important for
the development of novel strategies in the regulation of
body weight. BAT is active when its thermogenic func-
tion is stimulated [7], and accumulation of 2-deoxy-2-
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18F-fluoro-D-glucose [18F-FDG] is a direct consequence
of BAT activity [8]. Metabolic imaging of BAT using
18F-FDG positron-emission tomography [PET] was first
reported in a cold-activated BAT in rodents [9]. Conse-
quently, several 18F-FDG PET studies have been per-
formed in the cold in both humans (approximately 16°
C) [10] and rodents (approximately 4°C) [11] with some
degree of success [12]. In order to activate BAT at
ambient temperatures, several pharmacological chal-
lenges have been reported [13,14]. These include nico-
tine, caffeine, ephedrine, and norepinephrine, all of
which directly or indirectly stimulate the noradrenergic
receptors (Figure 1a).
b3-Adrenergic receptors [b3-AR] are found predomi-
nantly on brown adipocytes [15]. BAT is innervated by
the sympathetic nerves containing norepinephrine which
activates b3-AR (Figure 2). Exposure to cold tempera-
tures may promote metabolism indirectly through the
activation of b3-AR [16]. Efforts have been made to
develop b3-AR-selective agonists as possible therapeutic
agents for the treatment of obesity. (R, R)-5-[2-[2,3-(3-
chlorphenyl)-2-hydroxyethyl-amino]propyl]-1,3-benzo-
dioxole-2,2-dicarboxylate, disodium salt [CL316,243]
(Figure 1b) is a b3-AR-selective agonist. Binding affinity
of CL316,243 is low for the b1- and b2-ARs, thus exhi-
biting a > 10,000-fold selectivity (binding affinities of
CL316,243: Ki: b1 ≥ 10-4 M; b2 = 3 × 10-5 M; b3 = 3 ×
10-9 M) [17,18].
Chronic CL316,243 administration has been shown to
have an antiobesity effect in mice and rats [19,20].
Direct evidence on the ability of acute b3-AR stimula-
tion by CL316,243 to increase BAT metabolism in vivo
using PET has not been reported. Our goal in this study
was to quantitatively analyze 18F-FDG uptake in rats
treated with CL316,243 using PET and computed tomo-
graphy [CT]. The studies performed included the (1)
measurement of acute effects of CL316,243 to activate
and quantitate different BAT regions in the normal rat
at ambient temperature using 18F-FDG uptake; (2) eva-
luation of dose effects of CL316,243 in BAT activation;
(3) comparison of 18F-FDG uptake in cold temperature
and propranolol (a b-AR antagonist) in CL316,243-trea-
ted rats; and (4) evaluation of BAT histology of the con-
trol and CL316,243-treated rats.
Materials and methods
General methods
Radioactivity was counted using a CRC-R dose calibra-
tor (Capintec, Inc., Ramsey, NJ, USA), while low-level
counting (< 60 kcps) was done using a Caprac-R well
counter (Capintec, Inc.). An Inveon dedicated PET scan-
ner (Siemens Medical Solutions, Inc., Malvern, PA,
USA), which has a resolution of 1.46 mm in the center
of the field of view [21], was used for the PET studies.
An Inveon Multimodality [MM] CT scanner (Siemens
Medical Solutions, Inc.) was used for CT acquisitions in
combined PET/CT experiments. All in vivo and ex vivo
images were analyzed using ASIPro VM (Siemens Medi-
cal Solutions, Inc.), PMOD Software (PMOD Technolo-
gies Ltd., Zurich, Switzerland), and Inveon Research
Workplace [IRW] software (Siemens Medical Solutions,
Inc.). Slices of BAT were prepared using the CM1850
cryotome (Leica Microsystems Inc., Buffalo Grove, IL,
USA). Ex vivo 18F-FDG-labeled sections were exposed to
phosphor films and read using the Cyclone Phosphor
Imaging System (Packard Instruments, Meriden, CT,
USA) and were analyzed using the OptiQuant software
(Packard Instruments). All animal studies were approved
by the Institutional Animal Health Care and Use Com-
mittee of the University of California-Irvine.
Animals
Male Sprague-Dawley rats, aged 11 to 12 weeks, weigh-
ing 343 ± 9 g at the beginning of the experiment, were
used in this study. The rats were purchased from Harlan
Laboratories, Inc. (Placentia, CA, USA) and housed
under controlled temperatures of 22°C ± 1°C in a 12-h
light-dark cycle, on at 6 a.m., with water and food chow
ad libitum.
Experimental protocol
General procedures
All rats were fasted for 24 h before 18F-FDG administra-
tion. The control, cold-exposed, and CL316,243- (Tocris
Bioscience, Ellisville, MO, USA) and propranolol-pre-
treated (Sigma-Aldrich Corporation, St. Louis, MO,
USA) rats were administered intravenously [i.v.] with 14
± 1.5 MBq 18F-FDG under 2% isoflurane anesthesia. Fol-
lowing the injections, the rats were awake for 60 min
and subsequently placed in the supine position in a rat
holder and anesthetized with 2% isoflurane for upper-
body PET imaging. The rat holder was placed on the
PET/CT bed, and all animals had a CT scan after the
PET scan for attenuation correction and anatomical
delineation of PET images.
Drug effects
The control and CL316,243-pretreated rats (CL316,243,
2 mg/kg i.v., 30 min before 18F-FDG administration)
were anesthetized for upper-body PET imaging (n = 3,
each group). The same method of injection of 18F-FDG
was used for all rats, as was the recovery period and re-
anesthetization for PET. Dose effects of CL316,243 were
investigated by injecting 0.1, 0.5, and 1 mg/kg of
CL316,243 30 min prior to 18F-FDG administration. To
evaluate whether enhanced 18F-FDG uptake in activated
BAT could be reduced by pharmacologic interventions,
5 mg/kg propranolol was given intraperitoneally in the
anesthetized rats 30 min prior to CL316,243
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administration. Immediately after PET imaging, the rats
were sacrificed; BAT and white adipose tissue [WAT]
were harvested for autoradiography and counted in the
well counter.
Temperature effects
Cold-exposed rats (n = 3, each group; cold treatment
was at 8°C for 120 min prior to PET imaging) were
administered i.v. with 18F-FDG under 2% isoflurane
Figure 1 Chemical structures of compounds used to activate BAT and measured by 18F-FDG. Nicotine (1), caffeine (2), ephedrine (3), and
norepinephrine (4) (a) and CL 316,243 (b).
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anesthesia. During cold exposure, the rats were caged
alone without any sand bedding. Following the injec-
tions, the rats were awake for 60 min at ambient tem-
perature (for control) and 8°C (for cold treatment) and
subsequently anesthetized with 2% isoflurane for PET
imaging.
18F-FDG PET/CT imaging
The Inveon PET and MM CT scanners were placed in
the ‘docked mode’ for combined PET/CT experiments.
After 60 min of 18F-FDG uptake, the rats were anesthe-
tized and placed in supine position with their chest,
neck, and head within the field of view of the PET scan-
ner. PET data were acquired for 30 min, followed by a
CT scan (large area detector, 10 cm × 10 cm field of
view) for attenuation correction and anatomical delinea-
tion of PET images. The CT projections were acquired
with the detector-source assembly rotating over 360°
and 720 rotation steps. A projection bin factor of 4 was
used in order to increase the signal-to-noise ratio in the
images. The CT images were reconstructed using cone-
beam reconstruction with a Shepp filter with a cutoff at
the Nyquist frequency and a binning factor of 2, result-
ing in an image matrix of 480 × 480 × 632 and a voxel
size of 0.206 mm. The PET images were spatially trans-
formed to match the reconstructed CT images. PET
images were corrected for randoms, attenuation, and
scatter and were reconstructed as 128 × 128 × 159
matrices with a transaxial pixel of 0.776 mm and a slice
thickness of 0.796 mm using a fast maximum a
Figure 2 A schematic showing the activation of a brown adipose cell. (1) Agonists (norepinephrine and CL316,243) activate the b3-AR. (2)
Production of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) triggers lipase and hydrolysis of triglycerides. (3) The UCP-1
in the mitochondria increases the breakdown of fatty acids in the cell. (4) Increased metabolic activity in the mitochondria increases glucose and
18F-FDG uptake. (5) 18F-FDG-6-phosphate uptake in the cell increases and is measured by PET. (6) Outcome of this cascade of events is the
formation of heat.
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posteriori [fastMAP] algorithm in conjunction with
three-dimensional ordered subset expectation maximiza-
tion [OSEM3D] (2 OSEM3D iterations, MAP 18 itera-
tions, 0.1 smoothing factor). All images were calibrated
in units of becquerels per cubic centimeter by scanning
a 68Ge cylinder (diameter 6 cm) with a known activity
and reconstructing the acquired image with parameters
identical to those of 18F-FDG images.
Image analysis
18F-FDG quantitation
The magnitude of BAT 18F-FDG activation was
expressed as the standard uptake value [SUV] which
was defined as the average 18F-FDG activity in each
volume of interest [VOI] (in kilobecquerels per cubic
centimeter) divided by the injected dose (in megabec-
querels) times the body weight of each animal (in kilo-
grams). The SUVs were thus expressed in units of
[kilobecquerels per cubic centimeter per (megabecquerel
per kilogram)].
Volume measurement of BAT
The interscapular, cervical, periaortic, and intercostal
BAT were visualized on 3-D CT images with the 3-D
Visualization toolbox of the IRW software. For quantita-
tive analysis, VOIs were drawn on PET images using
PMOD. Similar to as described previously [22], the
VOIs were first delineated visually by contouring the
18F-FDG activity that was clearly above the normal
background activity (Figure 3).
In order to measure the volume of activated BAT, a
new VOI contour was delineated based on a threshold
equal to the mean 18F-FDG activity minus one standard
deviation of all voxels within the primary visually
defined VOI. The volume of the newly delineated VOI
was used to report the activated BAT volume.
Autoradiography
Transverse sections obtained from the soft tissue of the
interscapular BAT [IBAT] region at the level of T5 were
frozen on dry ice to provide 60-μm-thick slides for auto-
radiography. The slides were exposed to phosphor
screens for 1 h and scanned using the Cyclone Plus sto-
rage phosphor system. The acquired image was then
analyzed with the OptiQuant™ software where data in
each ROI were quantified in digital light units per milli-
meter squared [DLU/mm2].
To confirm IBAT activation, biopsies were taken
for histological evaluation (hematoxylin and eosin
[H&E] staining) using 20-μm-thick frozen sections.
Samples were viewed by light microscopy to deter-
mine the presence of multilocular droplets. Images
were saved as TIFF files (16 bits) and were quantified
using the ImageJ software for light intensity (range 0
to 256).
Statistical analysis
Statistical differences between groups were determined
using either independent Student’s t test or one-way
ANOVA with a Bonferroni post hoc test in the SPSS sta-
tistical software, version 16.0 for Windows (Chicago, IL,
USA). A p value of < 0.05 was considered to indicate
statistical significance.
Results
Acute effects of CL316,243
PET/CT images revealed intense 18F-FDG uptake in
IBAT of CL316,243-treated rats at ambient temperature
(Figure 4a). The effect of increased 18F-FDG was consis-
tent across animals treated with CL316,243. Treatment
of rats with CL316,243 (2 mg/kg) at ambient tempera-
ture, 30 min before 18F-FDG administration, increased
the total 18F-FDG uptake of IBAT to 22.7 ± 15.0 kBq/
cm3/(MBq/kg) which is about 12-fold greater (p <
0.001) compared to the 18F-FDG uptake in untreated
rats of 1.8 ± 0.8 kBq/cm3/(MBq/kg). This high amount
of 18F-FDG uptake in IBAT induced by CL316,243 was
decreased dramatically by preinjection of propranolol
(reduced by 96.0% to 0.9 ± 0.5 kBq/cm3/(MBq/kg), p <
0.001). Reduction in the levels of 18F-FDG in the pro-
pranolol-treated group is consistent with previous find-
ings on the effects of propranolol on BAT (Figure 4b).
Cold-temperature activation
For purposes of comparison of CL316,243-treated rats at
ambient temperature, the rats exposed to cold tempera-
tures also exhibited increases in 18F-FDG uptake of
IBAT (Figure 4a). However, the increase in the average
18F-FDG uptake of IBAT was only 1.1-fold over the con-
trol rats at ambient temperature (2.0 ± 0.9 vs. 1.8 ± 0.8
kBq/cm3/(MBq/kg), NS; Figure 4b). This increase in 18F-
FDG uptake is lower when compared to the effects of
CL316,243.
BAT subtypes
Treatment of rats with CL316,243 (2 mg/kg) at ambient
temperature increased the total 18F-FDG uptake of all
regions of BAT significantly. Activated interscapular,
cervical, periaortic, and intercostal BATs were clearly
observed in a 3-D analysis of 18F-FDG PET/CT images,
and regions were confirmed anatomically by CT coregis-
tration (Figure 4c; see Additional files 1 and 2). The
rank order of 18F-FDG uptake in the different BAT
areas was found to be IBAT = periaortic > cervical >
intercostal (Table 1). This regional distribution was con-
sistent among the different rats treated with CL316,243.
In the control rats, the order of 18F-FDG uptake was
similar but was approximately 10-fold lower. Smaller
areas such as the intercostal BAT were difficult to dis-
cern under control conditions.
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Volume of IBAT
The volume of the cold-activated IBAT increased 3.3-
fold (0.18 ± 0.08 vs. 0.057 ± 0.001 cm3, p < 0.001),
whereas the volume of the CL-activated IBAT increased
7.7-fold (0.44 ± 0.02 vs. 0.057 ± 0.001 cm3, p < 0.001)
compared to the control (Figure 5a). Propranolol
blocked the activation induced by CL316,243 and
reduced the IBAT-activated volume. Using 3-D PET
image analysis, distinct morphological features of IBAT
were discerned in CL316,243-treated rats as seen in
Figure 5b. The bilateral multilobular structure of IBAT
is shown in Figure 5c with the medial lobe (a) being lar-
ger and bifurcating and tapering to two smaller lobes (b
and c). This structure of IBAT was seen with approxi-
mately a similar profile bilaterally. Based on the 18F-
FDG uptake of IBAT, greater activation of IBAT begins
in the medial parts of the lobe (a) and progresses later-
ally in the lobes (b) and (c). This morphology of IBAT
was consistent in several animals that were treated with
CL316,243.
Figure 3 Coronal, sagittal, and transverse views of PET/CT images. The images show how automatic contour VOIs were drawn on the
CL316,243-activated BATs: PET (left), CT (middle), and fused PET/CT (right).
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CL 316,243 dose effects
Rats treated acutely with 2 mg/kg of CL316,243 did not
show any pharmacological effects and any changes in
vital signs. Since chronic studies in rats with lower
doses of CL316,243 have been reported, we evaluated a
CL316,243 dose-dependent relationship on 18F-FDG
uptake. Compared to the 12-fold increase by 2 mg/kg,
average 18F-FDG uptake of IBAT increased 3.6-, 3.4-,
and 7.6-fold using doses of 0.1, 0.5, and 1 mg/kg CL,
respectively (Figure 6). A fivefold increase in the
CL316,243 dose did not significantly affect IBAT 18F-
FDG uptake.
Autoradiography
IBAT isolated from the control and CL316,243-treated
rats had distinct features as seen in Figure 7a.
Figure 4 Transverse views and quantitative and 3-D analyses of PET/CT images. Transverse views of PET/CT images: PET (left), CT (middle),
and fused PET/CT (right) show intense 18F-FDG uptake in the CL-activated IBAT, but faint uptakes in the control and the cold-activated IBAT and
scarce uptake in the propranolol-treated group (a). Quantitative analysis of PET/CT images for IBAT uptake in four studied groups (b). Data are
mean ± SD; p < 0.001 as compared to the control (asterisk), cold-exposed (dagger), and propanolol-treated (double dagger) rats. 3-D analysis of
PET (right) and PET/CT (left) images clearly showing interscapular, cervical, periaortic, and intercostal BATs (c).
Table 1 18F-FDG in different BAT regions in the rat
BAT type Controla
(kBq/cm3/(MBq/kg))
CL316,243a
(kBq/cm3/(MBq/kg))
Ratio
(CL/control)
Interscapular 1.8 ± 0.8 22.7 ± 15 12.6
Cervical 1.7 ± 0.4 16.3 ± 6.2 9.6
Periaortic 2.5 ± 1.1 23.2 ± 11.6 9.3
Intercostal NA 9.7 ± 2.2 NA
aMean ± SD, n = 3 measured in PET/CT experiments with regions of BAT identified in PET/CT images as shown in Figure 1c; NA, the regions of intercostal BAT in
the control animals were unidentifiable due to their small size and very low activity; BAT, brown adipose tissue; CL316,243, (R, R)-5-[2-[2,3-(3-chlorphenyl)-2-
hydroxyethyl-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate, disodium salt.
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Treatment with CL316,243 induced clear differentiation
of large BAT areas compared to the control rats. These
BAT areas in CL316,243-treated animals had significant
amounts of 18F-FDG uptake as seen in autoradiographic
images of the transverse sections obtained from the
IBAT region. Muscle and WAT areas seen in the histo-
logic consecutive sections showed little 18F-FDG uptake.
The quantitative data of the autoradiography and
autopsy measures in the IBAT and WAT regions are
summarized in Table 2. The control animals showed an
IBAT/WAT ratio of approximately 3, while the ratio of
CL316,243-treated rats was significantly higher, consis-
tent with what is seen in the images in Figure 7a.
Histology analysis
Staining IBAT of the control animals with H&E showed
multiocular cells containing numerous lipid vacuoles
which were scarce in the BAT of the CL316,243-treated
animals (Figure 7b). The quantitative data of the histol-
ogy studies showed that the total lipid content of the
activated IBAT was significantly reduced (average light
intensity 176 ± 2.0 vs. 188 ± 3.5, p < 0.004; Figure 7c).
There was no significant difference in the WAT lipid
content between the two conditions both visually and
quantitatively (data not shown).
Discussion
Our findings support the sympathetic and sensory
innervations of BAT where stimulation of b3-adreno-
ceptors using a selective b3-agonist turns on a cascade
of intracellular events ending in hypermetabolism as
depicted in Figure 4c and in the Additional files for Fig-
ure 4c. In this work, activation of the b3-adrenoceptors
using CL316,243 at ambient temperature was able to
rapidly stimulate BAT and trigger the uptake of 18F-
FDG in different regions of the body known to contain
BAT. This high degree of 18F-FDG enabled the delinea-
tion of the extent of different BAT areas including inter-
scapsular, periaortic, cervical, and intercostal BATs. It
also provided morphological lobular features of IBAT
which consists of bilateral lobes at the midline between
the T4 to T6 vertebrae, and each lobe extends and
Figure 5 PET/CT images and their quantitative analysis and the
pictorial representation of IBAT. (a) Quantitative analysis of PET/
CT images for IBAT volume in the four studied groups. Data are
mean ± SD; p < 0.001 as compared to the control (asterisk), cold-
exposed (dagger), and propanolol-treated (double dagger) rats. (b)
3-D PET images of IBAT: ventral, dorsal, and caudal views. (c)
Pictorial representation of the lateral and dorsal views of IBAT
showing a bilateral structure where the medial portions (a) are
located near or between T3 and T4 and extends posteriorly and
bifurcates (b) and tapers until T6.
Figure 6 Quantitative analysis of CL316,243 dose effects on
IBAT activity obtained from PET images. P < 0.01 as compared
to the control (asterisk) and CL316,243-pretreated (0.1 and 0.5 mg/
kg) groups (dagger).
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bifurcates laterally (Figure 5b, c). The periaortic BAT
was visualized as a large region extending along the ver-
tebral column.
Quantitative increase of 18F-FDG in the CL316,243-
treated IBAT was more than 12-fold compared to that in
the control rats at ambient temperature, and the volume
of the activated BAT was over sevenfold compared to the
controls. This increase is substantially higher than that of
previously reported pharmacological challenge studies
using nicotine and ephedrine [13]. Because of the selec-
tive nature of CL316,243, it may be inferred that the
increase in 18F-FDG uptake occurred due to the stimula-
tion of the b3-adrenoreceptor. Propranolol, a nonselec-
tive b-blocker, inhibited CL316,243-induced BAT
activation to below control levels and confirmed the like-
lihood of action of CL316,243 via the b3-adrenoceptor.
Activation of BAT by cold exposure has been studied
by PET [9]. Long time exposure to cold temperature
prior to PET was used to visualize the presence of BAT.
However, the difficulty of this method is the variations
in sympathetic responses to low temperature in different
rats, reducing the reliability of the imaging method. The
effect of cold activation on BAT in this study is smaller
than that in previous reports [9,11,13] and may be due
to the difference in duration and the intensity of cold
exposure reported previously (4°C for 4 h).
Our findings of a significant increase in 18F-FDG
uptake in BAT from a very low dose of CL316,243 (0.1
mg/kg) may suggest a direct role of stimulation of b3-
AR. This is consistent with the reported effects of
CL316,243 on the overall energy expenditure in BAT
[19]. At higher doses, the volume of hypermetabolic
BAT increased significantly. Although CL316,243 pro-
motes BAT mitochondrial proliferation, it is unclear if
the increases in BAT volume in 18F-FDG PET are due
to an increase in both brown adipocyte activation and
proliferation. Energy expenditure in brown fat is capable
of ranging over many orders of magnitude, controlled
primarily by sympathetic stimulation. Increases in
uncoupled respiration are mediated by rapid changes in
UCP intrinsic activity (within seconds), increases in the
amount of UCP per cell (within hours), increases in the
number of mitochondria per adipocyte (within days),
and finally, hyperplasia of brown adipocytes (over days
to weeks) [23].
In the early stages of exposure to cold temperatures,
mobilization of fatty acids from WAT is also known to
be a primary source for the activation of BAT rather
Figure 7 Autoradiographic images and H&E-stained sections
and their quantification. Ex vivo 18F-FDG autoradiography of BAT
(upper row) showing intense uptake in the CL316,243-activated IBAT
(right) as compared to the control (left). Consecutive sections of
autoradiographic images (lower row) showing IBAT marked by
arrows (a). H&E-stained sections of control IBAT showing multiocular
cells (×200 original magnification) which disappeared when they
get activated by CL316,243 (b). Quantification of the H&E-stained
sections in both groups (c). Data are mean ± SD; p < 0.004 as
compared to the control (asterisk).
Table 2 Ex vivo measures of 18F-FDG in IBAT and WAT
Groups IBAT WAT Ratio (IBAT/WAT)
Autorada
(106 DLU/mm2)
Autopsyb
(kBq/g/(MBq/kg))
Autorada
(106 DLU/mm2)
Autopsyb
(kBq/g/(MBq/kg))
Autorada
(106 DLU/mm2)
Autopsyb
(kBq/g/(MBq/kg))
Control 1.6 ± 0.2** 4.3 ± 0.4** 0.5 ± 0.1 1.6 ± 0.1 3.2 ± 0.2 2.7 ± 0.1
CL316,243-treated 13.7 ± 0.1*, ** 68.1 ± 18.0*, ** 1.1 ± 0.3* 2.4 ± 0.2* 12.5 ± 3.3* 27.6 ± 5.5*
aResults of autoradiography in transverse sections of IBAT and the surrounding WAT mean ± SD, n = 3; *p < 0.05 as compared to the control; **p < 0.05 as
compared to WAT; bResults of counted radioactivity concentrations in autopsied IBAT and the surrounding WAT mean ± SD, n = 3; *p < 0.05 as compared to the
control; **p < 0.05 as compared to WAT. IBAT, interscapular brown adipose tissue; WAT, white adipose tissue; CL316,243, (R, R)-5-[2-[2,3-(3-chlorphenyl)-2-
hydroxyethyl-amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate, disodium salt.
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than the breakdown of fat depot stored in BAT [24].
Our histology studies showed that the number of lipid
vacuoles in BAT was substantially decreased after stimu-
lation by CL316,243, while there was no significant
change in the WAT lipid content between the two con-
ditions. Therefore, we believe that in the acute adminis-
tration of CL316,243, glucose metabolism and lipolysis
of stored lipids in BAT are primary sources for the acti-
vation of the tissue rather than the mobilization of fatty
acids from WAT. Although 18F-FDG uptake on PET/CT
scans is generally known to represent activation of BAT,
one may argue that the observed effect of the agonist
might be merely due to a shift in basal BAT metabolism
from fatty acids to glucose [25]. Our data confirm an
increase in BAT metabolism due to both lipolysis and
glucose uptake.
Autoradiography and excised tissue 18F-FDG concen-
tration demonstrated that 18F-FDG uptake is specific to
BAT. Small effects of CL316,243 on WAT 18F-FDG
uptake were observed. The appearance of brown adipo-
cytes in white fat depots has been recently reported
[26]. The origin of these brown adipocytes in WAT is
still uncertain, and it is not clear whether these cells
develop through differentiation of specific precursors or
from white adipocytes. 18F-FDG PET/CT is a good ima-
ging tool for measuring small changes in BAT activity
and perhaps dispersed brown adipocytes activated by
b3-adrenergic agonists or other BAT-activating agents.
Conclusion
Our results suggest that CL316,243 significantly acti-
vates BAT, measurable by 18F-FDG uptake at ambient
temperature in the rodent model. This is consistent
with the b3-adrenoreceptor-mediated metabolic increase
in BAT and provides a mechanism to enhance and
study BAT activity. b3-AR agonists are potential targets
for the pharmacotherapy of obesity and diabetes; how-
ever, a better understanding of the mechanisms underly-
ing the metabolism of BAT is needed which will
advance management of obesity and diabetes.
Additional material
Additional file 1: Projection 18F-FDG PET image. Projection 18F-FDG
PET image of a CL316,243-treated rat showing the BAT, brain, and
Harderian glands.
Additional file 2: Projection 18F-FDG PET/CT image. Projection 18F-
FDG PET/CT image of a CL316,243-treated rat showing the BAT and
Harderian glands.
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